

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 November 2024 (14.11.2024)



(10) International Publication Number
WO 2024/231442 A1

(51) International Patent Classification:
A61K 47/60 (2017.01) *A61P 35/00* (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2024/062703

Published:

(22) International Filing Date:
08 May 2024 (08.05.2024)

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/501,115 09 May 2023 (09.05.2023) US
63/578,017 22 August 2023 (22.08.2023) US
63/591,684 19 October 2023 (19.10.2023) US

(71) Applicant: **ASCENDIS PHARMA ONCOLOGY
DIVISION A/S** [DK/DK]; Tuborg Boulevard 12, 2900
Hellerup (DK).

(72) Inventors: **MILLER BREINHOLT, Vibeke**; c/o As-
cendis Pharma A/S, Tuborg Boulevard 12, 2900 Hellerup
(DK). **SINGEL, Stina**; c/o Ascendis Pharma, Inc, 1000
Page Mill Rd., Palo Alto, California 94304 (US). **LANÇA,
Telma**; c/o Ascendis Pharma A/S, Tuborg Boulevard 12,
2900 Hellerup (DK). **KURPIERS, Thomas**; c/o Ascendis
Pharma GmbH, Im Neuenheimer Feld 584, 69120 Hei-
delberg (DE). **KNAPPE, Thomas**; c/o Ascendis Pharma
GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg (DE).

(74) Agent: **BÜCHEL, Edwin**; Patentanwälte Isenbruck Bösl
Hörschler PartG mbB, Seckenheimer Landstraße 4, 68163
Mannheim (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: NOVEL CANCER TREATMENTS WITH IL-2 CONJUGATES

(57) Abstract: The present invention relates to an IL-2 conjugate or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, wherein the IL-2 conjugate is administered in a dose ranging from 80 µg IL-2/kg to 160 µg IL-2/kg and wherein the IL-2 conjugate is of formula (I); and to related aspects.

WO 2024/231442 A1